Lumena files for IPO

Lumena Pharmaceuticals Inc. (San Diego, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Citigroup; Cowen; and Leerink. The offering comes on the heels of a $45 million series B round that Lumena secured last month (see BioCentury, March 17).

Lumena's LUM001 is in Phase II testing for four Orphan indications: adults with primary biliary cirrhosis (PBC); children with Alagille syndrome; children with progressive familial intrahepatic cholestasis (PFIC); and adults with primary sclerosing cholangitis (PSC). Data from the Alagille trial are expected next half; data from the remaining Phase II trials are expected by late this year or early next year. ...